Skip to content

Myrtelle

3 viewers · 30d

Total raised

$24.2M

+$16.7M this year

2 filings since 2025 · latest SAFE filed

Cumulative raised
LAST ROUND
SAFE · $16.7M
ROUNDS
2
INVESTORS
1
FOUNDED
2021
HQ
New York, NY
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

Myrtelle Inc. is a clinical-stage gene therapy company carrying the mission of developing innovative treatments for neurodegenerative diseases that primarily affect myelin and white matter in the brain. With a particular focus on Canavan disease, the company addresses critical gaps in treatment options for rare genetic disorders of the central nervous system, aiming to improve patient outcomes significantly.

What sets it apart

Myrtelle stands out due to its advanced gene therapy approach utilizing proprietary adeno-associated virus (AAV) technology tailored to treat complex neurological disorders.

Funding history

2 rounds
SAFE+2Jun 22, 2026 · $25K min
Form D
+$16.7M$24.2M total
DebtMar 12, 2025 · $50K min
Form D
+$7.5M$7.5M total

Products

1 tracked

rAAV-Olig001-ASPA

Gene Therapy

rAAV-Olig001-ASPA is an investigational gene therapy specifically designed to treat Canavan disease, a severe childhood genetic disorder characterized by the degeneration of white matter in the brain.

  • Utilizes proprietary adeno-associated virus (AAV) vector technology
  • Delivers a functional copy of the ASPA gene directly to oligodendrocytes
  • Administered via intracerebroventricular injection for effective brain cell targeting
  • Early trials showing reductions in disease biomarkers and improvements in white matter

Links

WebsiteSEC EDGAR filings